证券代码：688393 证券简称：安必平 公告编号：2025-023 广州安必平医药科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 15 日 （二） 股东大会召开的地点：广州市黄埔区科信街 2 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 29 | | --- | --- | | 普通股股东人数 | 29 | | 2、出席会议的股东所持有的表决权数量 | 32,883,491 | | 普通股股东所持有表决权数量 | 32,883,491 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 35.1441 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 35.1441 | 审议结果：通过 （四） ...

Investment Rating - The report maintains an investment rating of "Outperform the Market" for the medical device industry [2]. Core Insights - The report emphasizes that AI in healthcare is restructuring diagnostic and treatment processes, creating investment opportunities driven by efficiency and market growth. The global healthcare sector faces challenges such as aging populations and uneven distribution of medical resources, which AI can address by optimizing the healthcare value chain and promoting equitable access to medical resources [5][6]. Summary by Sections 1. AI Healthcare Development Environment - The domestic AI healthcare development environment is mature, supported by data resources and services that enhance algorithm accuracy and generalization [11]. - AI technology is breaking the uneven distribution of medical resources, addressing the growing demand for healthcare services due to an aging population [18][19]. 2. AI Medical Imaging - AI medical imaging is the most mature application of AI in healthcare, with a complete ecosystem covering various imaging modalities such as CT, MRI, and X-ray. The market for AI medical imaging in China is projected to reach 6.17 billion yuan by 2025 [5][39]. - Companies like Mindray and United Imaging are leveraging hardware advantages to build "device + AI" ecosystems, while pure AI companies focus on lesion recognition and cross-disease generalization capabilities [5][39]. 3. AI In Vitro Diagnostics - The AI in vitro diagnostics market is rapidly growing, with applications in hematology, microbiology, and pathology. Companies like BGI and Anbiping are innovating with AI-driven solutions to enhance diagnostic efficiency [5][6]. 4. AI Wearable Devices - AI wearable devices are transforming health management by providing real-time monitoring and data analysis, becoming essential for chronic disease management. The market for smart wearable devices in China is expected to exceed 15 billion yuan in 2023 and reach 33 billion yuan by 2026, with a compound annual growth rate of 18.1% [6]. 5. Investment Recommendations - The report suggests that the industry is poised for multidimensional development, transitioning from scale expansion to higher-level growth. It highlights long-term investment opportunities in leading companies like Mindray, United Imaging, Yuyue Medical, and Kefu Medical, which are early adopters of AI healthcare solutions [6].

Core Viewpoint - Anbiping's stock price closed at 30.88 yuan, down 4.28%, with a rolling PE ratio of 1291.34 times, significantly higher than the industry average [1] Company Summary - Anbiping's main business includes tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - The latest performance report for Q1 2025 shows a revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1] Industry Summary - The average PE ratio for the medical device industry is 48.98 times, with a median of 36.16 times, placing Anbiping at the 121st position in the industry ranking [2] - The total market capitalization of Anbiping is 2.889 billion yuan [2] - As of Q1 2025, there are 7 institutions holding shares in Anbiping, with a total holding of 26.54 million shares valued at 949.7 million yuan [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688393 证券简称：安必平 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元币种：人民币 (二) 非经常性损益项目和金额 √适用 □不适用 单位:元币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 (三) 主要会计数据、财务指标发生变动的情况、原因 √适用 □不适用 ...

广州安必平医药科技股份有限公司 2024 年年度股东大会会议资料 公司代码：688393 公司简称：安必平 广州安必平医药科技股份有限公司 | 2024 年年度股东大会会议须知 . | | --- | | 2024 年年度股东大会会议议程 . | | 2024 年年度股东大会会议议案 . | | 议案一 关于《公司 2024 年年度报告》及其摘要的议案 | | 议案二 关于《2024 年度董事会工作报告》的议案 | | 议案三 关于《2024年度独立董事述职报告》的议案 ……………………………………………………15 | | 议案四 关于《2024 年度监事会工作报告》的议案 | | 议案五 关于 2024 年年度利润分配预案的议案 . | | 议案六 关于续聘会计师事务所的议案 | | 议案七 关于《2024年度财务决算报告》的议案 | | 议案八 关于提请股东大会授权董事会以简易程序向特定对象发行股票的议 | | 安 术 | | 议案九 关于补选非职工代表监事的议案 - | 广州安必平医药科技股份有限公司 2024 年年度股东大会会议资料 2024 年年度股东大会 会议资料 2024 年年度股东大会会议须知 ...

一、监事会会议召开情况 广州安必平医药科技股份有限公司(以下简称"公司")第四届监事会第七 次会议于 2025 年 4 月 29 日在公司会议室以现场和通讯相结合的方式召开。本 次会议的通知于 2025 年 4 月 25 日以电子邮件方式送达至公司全体监事。本次 会议由全体监事共同推举职工代表监事金信汝女士主持，会议应参与表决的监 事 3 名,实际参与表决的监事 3 名。本次会议的召集、召开符合相关法律、法规、 规则及《公司章程》的有关规定。 二、监事会会议审议情况 与会监事经过认真审议,形成如下决议： 证券代码：688393 证券简称：安必平 公告编号：2025-022 广州安必平医药科技股份有限公司 第四届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 表决结果：同意 3 票，反对 0 票，弃权 0 票 具体内容详见公司同日在上海证券交易所（www.sse.com.cn）披露的《关 于作废部分已授予尚未归属的 2022 年限制性股票的公告》（公告编号：2025- 021）。 特此公告。 广州 ...

表决结果：3 票同意，0 票反对，0 票弃权。 独立董事：吴翔、彭文平、吴红日 2025 年 4 月 25 日 广州安必平医药科技股份有限公司（以下简称"公司"）第四届董事会独立 董事专门会议第六次会议于 2025 年 4 月 25 日（星期五）在公司 A102 会议室以 现场结合通讯的方式召开。会议通知已于 2025 年 4 月 22 日通过邮件的方式送达 各位独立董事。本次会议应出席独立董事 3 人，实际出席独立董事 3 人。 会议由吴翔主持，会议召开符合有关法律、法规、规章和《公司章程》的 规定。经各位独立董事认真审议，会议形成了如下决议： 一、审议通过《关于作废部分已授予尚未归属的 2022 年限制性股票的议案》 本次部分限制性股票的作废符合《上海证券交易所科创板股票上市规则》《上 市公司股权激励管理办法》以及公司《2022 年限制性股票激励计划（草案）》 中的相关规定，所作的决定履行了必要的程序。因此，我们同意公司此次作废部 分已授予尚未归属的 2022 年限制性股票。 广州安必平医药科技股份有限公司 广州安必平医药科技股份有限公司 第四届董事会独立董事专门会议第六次会议决议 ...

证券代码：688393 证券简称：安必平 公告编号：2025-021 广州安必平医药科技股份有限公司 关于作废部分已授予尚未归属的 2022 年限制性股票 的公告 （四）2022 年 4 月 22 日，公司召开 2021 年年度股东大会，审议并通过了 《关于公司<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司 <2022 年限制性股票激励计划实施考核管理办法>的议案》以及《关于提请公司 股东大会授权董事会办理股权激励相关事宜的议案》，并于 2022 年 4 月 23 日在 上海证券交易所网站（www.sse.com.cn）披露了《广州安必平医药科技股份有限 公司关于 2022 年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票 情况的自查报告》（公告编号：2022-019）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州安必平医药科技股份有限公司（以下简称"公司"）分别于 2025 年 4 月 25 日召开第四届董事会独立董事专门会议第六次会议，2025 年 4 月 29 日召 开的第四届 ...

Financial Performance - The company's revenue for Q1 2025 was ¥72,543,474.19, a decrease of 28.51% compared to ¥101,468,637.22 in the same period last year[3] - The net profit attributable to shareholders was -¥11,064,498.81, representing a decline of 238.49% from ¥7,989,313.63 in the previous year[3] - The basic earnings per share were -¥0.12, a decline of 233.33% from ¥0.09 in the same period last year[3] - The diluted earnings per share were also -¥0.12, down 250.00% from ¥0.08 in the previous year[4] - Net profit for Q1 2025 was a loss of ¥12,249,821.81, compared to a profit of ¥3,781,976.65 in Q1 2024[15] - The net profit attributable to shareholders of the parent company for Q1 2025 was a loss of ¥11,064,498.81, compared to a profit of ¥7,989,313.63 in Q1 2024[17] Cash Flow - The net cash flow from operating activities improved to ¥3,888,748.24, a significant increase of 115.89% compared to -¥24,475,755.67 in the same period last year[3] - Cash inflow from operating activities in Q1 2025 was ¥106,136,985.63, slightly up from ¥105,904,561.62 in Q1 2024[18] - Cash outflow from operating activities in Q1 2025 was ¥102,248,237.39, down from ¥130,380,317.29 in Q1 2024[18] - The net cash flow from operating activities was $3,888,748.24, a decrease of $24,475,755.67 compared to the previous period[19] - The net cash flow from financing activities was -$5,601,723.19, compared to -$20,374,537.97 in the previous period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,329,718,266.26, a decrease of 2.42% from ¥1,362,730,307.94 at the end of the previous year[4] - The company's current assets totaled RMB 652,395,028.10, down from RMB 692,252,007.28, indicating a decrease of about 5.8%[12] - Cash and cash equivalents decreased significantly from RMB 95,146,930.50 to RMB 48,058,624.00, representing a decline of approximately 49.5%[11] - The company's total liabilities decreased from RMB 130,988,198.25 to RMB 109,729,311.26, a decline of about 16.2%[13] - The company's equity remained stable with total equity at RMB 1,219,988,955.00 as of March 31, 2025[13] Research and Development - Research and development expenses totaled ¥10,765,339.05, accounting for 14.84% of revenue, an increase of 3.78 percentage points from 11.06% in the previous year[4] - Research and development expenses for Q1 2025 were ¥9,284,399.55, an increase of 6.2% from ¥8,740,663.97 in Q1 2024[14] Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,309[8] - The company has not reported any significant changes in shareholder structure or participation in margin trading activities during the reporting period[10] Other Financial Metrics - The weighted average return on equity was -0.88%, a decrease of 1.51 percentage points from 0.63% in the previous year[4] - The company reported non-recurring gains and losses totaling ¥1,903,245.37 for the period[5] - The company experienced a credit impairment loss of ¥1,143,895.30 in Q1 2025, compared to a gain of ¥1,881,551.59 in Q1 2024[15] - The company reported a significant increase in sales expenses, totaling ¥37,379,708.06 in Q1 2025, compared to ¥43,232,342.70 in Q1 2024[14] Investment Activities - The total cash inflow from investment activities was $111,653,702.20, up from $55,249,254.58 in the prior period[19] - The net cash outflow from investment activities was $43,628,071.03, a significant decline from a net inflow of $25,539,718.26 previously[19] Accounting Standards - The company will not apply new accounting standards starting from 2025[20]